Phase II study of spirogermanium in advanced ovarian malignancy.
In the present phase II trial 18 heavily pretreated patients with advanced ovarian malignancy were treated with spirogermanium, 11 im and seven iv. Objective responses (partial remission) were obtained in two (11%) of the 18 patients, with a remission duration of 5 and 23 + months, respectively. An additional four (22%) patients had stable disease. Each of these six patients had a better quality of life. There were few side effects. Myelosuppression, nausea, or other gastrointestinal side effects did not occur. The present investigation shows that spirogermanium is useful as a palliative chemotherapeutic agent in patients with advanced ovarian malignancy.
D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003536:Cystadenocarcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005857:Germanium / Q000627:therapeutic use*; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009942:Organometallic Compounds; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012075:Remission, Spontaneous; D013141:Spiro Compounds / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013141:Spiro Compounds; D005857:Germanium; C026818:spirogermanium